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Abstract
Treatment of cancer is currently based on three main modalities: surgery, radiothera‐
py and chemotherapy. Most solid tumours can only be cured at an early stage, due to
the lack of effective systemic treatment. Surgery and radiotherapy are highly effective
for eradicating localized tumours, but unfortunately cannot target disseminated dis‐
ease. Chemotherapy represents systemic treatment, but the clinical use of current
drugs is to a large extent hampered by their limited specificity.
Over the last two decades, immunotherapy has emerged as an interesting novel
approach. Contrary to the traditional treatment modalities, the immune system
combines inherent specificity with a systemic range of action.
The term “vaccine” is traditionally used to describe substances that protect against
the development of infectious diseases. In cancer therapy, this term refers to both
therapeutic and prophylactic approaches for eliciting immunological and anti-tumour
responses.
Prophylactic vaccines have only been developed in a few cancer forms, mainly cancers
related to viral infection, such as cervical and hepatocellular carcinoma. Therapeutic
vaccines, given to patients after the development of the disease, are however
investigated in a number of cancer forms. Some of the therapeutic vaccines may also
be used for prophylaxis, particularly in patients with increased risk of cancer process.
This paper throws light and depicts the international experience of a number of
distinguished researchers in the field of development and testing of vaccines against
some tumours, mainly malignant melanoma and prostate cancer.
Keywords: Immunotherapy, anti-tumour vaccine, malignant melanoma, prostate can‐
cer
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1. Introduction
The author analyzes the experience and the research projects worked out in the Dept. Cell
Therapy of the University Hospital “Radium” (Inst. Cancer Research, Oslo, Norway) by the
team of Prof. Gunnar Kvalheim, Prof. Jon Kyte, Prof. Jahn Nesland, the Bulgarian immunol‐
ogist M.Sc. Biol. Paula Lazarova, and the author himself, for the last several years.
The colleagues from Radium have utilized gene-transfer technology for developing vaccine
therapy with dendritic cells transfected with tumour-mRNA. These vaccines are designed to
combine the immunostimulatory capacity of dendritic cells with the antigen repertoire of
tumour cells.
There are two approaches to the project: preclinical/experimental evaluation and clinical trials
on patients.
2. The first glance throws light on
2.1. Metastatic malignant melanoma – Prognosis and treatment
Malignant melanoma (MM) is among the most common cancers in the developed countries
and the incidence has increased substantially over the last decades. Surgery is frequently
curative at an early stage, but the prognosis for patients with disseminated disease is generally
bleak, with a medium survival of 6-10 months and a 5-year survival of about 5% only.
Decarbazin is extensively used for treatment of metastatic melanoma and has been reported
to induce objective tumour responses in 5-29% of all patients. A number of studies have
compared other single agents or multi-drug regimes to Decarbazin, without demonstrating a
superior effect. To date, no randomized controlled trials have demonstrated improved survival
after treatment with Decarbazin or any other drug.
Furthermore, there have been numerous reports of spontaneous immune responses [1] in
melanoma patients, to some extent associated with a favourable clinical development. This
has prompted the development of various vaccines [1] to target defined or undefined mela‐
noma antigens.
Immunological responses against vaccine antigens have been demonstrated in a number of
studies [2, 3, 4, 5, 6, 7, 8], but there is limited evidence of clinical effect
With regard to non-specific immunostimulation, high-dose interleukin-2 (IL-2) has been
shown to induce complete remission in about 16% of melanoma patients, but is associated with
considerable adverse effects. IL-2, Interferon-alpha (INF-alpha) and other cytokines are also
investigated in combination with conventional chemotherapy. Adjuvant therapy with IFN-
alpha is believed to prolong the disease-free period, but most studies do not indicate improved
survival. Taken together, there is an urgent need for improved therapy of metastatic malignant
melanoma.
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2.2. The second glance throws light on: Metastatic prostate cancer – Prognosis and treatment
Prostate cancer is the most commonly diagnosed cancer in the male population of the devel‐
oped countries world-wide. Though the majority of patients eventually die of other causes,
prostate cancer is also among the most common cause of cancer death among males in Europe,
North America and Japan.
Metastatic prostate cancer is usually treated with bilateral orchiectomy and/or androgen
suppressive drugs. The resulting androgen deprivation frequently induces tumour regression
and has a palliative effect. The treatment is also considered to give prolonged survival for
subsets of patients. However, after a transient response period (median 12-24 months),
virtually all patients develop progressive cancer refractory to hormone therapy.
In the RNA/DC-vaccine trial performed in Radium, all included patients had hormone
refractory prostate cancer (HRPC).
At this advanced stage, the median survival is only 10-12 months. There has been no effective
therapy for HRPC, and many physicians have thus recommended ‘clinical observation’.
It is interesting that some separate trials, in other oncology centers, demonstrated prolonged
survival after treatment with Doxetacel. This finding has been confirmed in subsequent
studies, and Doxetacel is now considered as standard therapy for patients with HRPC.
It should be recalled, however, that the effect on mean survival is limited (2-3 months). Patients
with HRPC may also to some extent benefit from different forms of palliative treatment,
including certain cytotoxic drugs, bisphosphonates, second-line hormonal agents, glucocorti‐
coids and radiation therapy.
There is, however, an evident need for improved systemic treatment, and immunotherapy
may represent an attractive option. Several small-scale studies [2, 3, 5] have demonstrated
promising immune responses after vaccine therapy, but there is limited evidence of clinical
affect. Interestingly, a recent placebo-controlled phase III trial on HRPC patients has suggested
a possible survival benefit from therapy with dendritic cells (DCs) pulsed with a fusion protein
of prostatic acid phosphatase and granulocyte-macrophage colony-stimulating factor (GM-
CSF).
3. General background for cancer immunotherapy
3.1. Immunosurveillance and immunoediting
A tumour-specific immune response will depend on the ability of immune cells to discriminate
the tumour from normal host tissues. In contrast to infectious microbes and allogeneic human
cells, the tumour cells are largely similar to normal host cells. According to the theory of
immunosurveillance, as suggested by Burnet in 1970, the immune system is still able to
recognize and eliminate tumour cells. This concept was severely challenged in the following
years. However, there is now convincing evidence that the immune system may recognize
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tumour cells due to their expression of altered antigens. The early concept of tumour surveil‐
lance has highlighted the importance of the immune system in protecting against cancer.
Recent modifications of this theory, now named immunoediting, provide increased insight
into the role of the immune system in sculpting the tumour into an immunologically selected
cell population. The immunoediting perspective points to a major challenge in cancer immu‐
notherapy: how to make the immune system destroy a tumour that has already escaped the
immune attack.
A solution may be found in exploiting the difference between spontaneously occurring
immune activation and optimally engineered immunization. This is the reason for the
developing of immune-gene-therapy with tumour-mRNA transfected dendritic cells.
3.2. Activation of T cells that recognized tumour-associated antigens
T-lymphocytes express antigen-specific T-cell receptors (TCRs) that enable them to recognize
target cells expressing a particular antigen. The antigens are presented as peptides on HLA-
molecules on the target cell surface, and the recognition is mediated by binding of the T-cell
receptor to the HLA/peptide complex. Proper T-cell stimulation, including TCR-binding, leads
to activation and clonal expression of T cells with the relevant antigen specificity. During the
development of a tumour, numerous mutations result in novel antigens and altered expression
of normal antigens. The resulting tumour-associated antigens are presented as peptides on
HLA-molecules.
Figure 1a shows how host T cells may recognize tumour cells by binding of the TCR to the
HLA/peptide complex [7]. However, TCR-binding does not necessarily lead to T-cell activa‐
tion. In general, the activation of previously unstimulated T cells (‘naïve’ T cells) requires
additional stimulation through co-stimulatory molecules like CD80 and CD86. If stimulated
only through the TCR, the naïve T cells enter a stage of anergy and permanently lose their
ability to be properly activated. The expression of co-stimulatory molecules is largely restricted
to professional antigen presenting cells (APCs), including dendritic cells (DCs), macrophages
and B cells [7].
Two major subsets of T cells exist. CD4+ T cells recognize peptides bound to HLA class II,
while CD8+ T cells recognize peptides presented on HLA class I (Figure 1b).
Most human cells, except erythrocytes and testicular cells, express HLA class I. In contrast,
HLA class II is expressed mainly by professional APCs, activated T cells and the cortical
epithelium in the thymus. Thus, CD8+ T cells may be stimulated by most cells, while CD4+ T
cells depend on stimulation from APCs. As it will be discussed a bit later, the activation of
both T-cell subsets is probably important for an effective anti-tumour response.
Effector T cells and the Th1/Th2 delineation [7]:
Proper T-cell activation results in differentiation into effector T cells. CD8+ effector T cells are
cytotoxic, i.e. capable of killing cells that express the relevant antigen (Figure 1c).
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Figure 1. a) Mutations through the development of tumor lead to expression of mutated proteins. The mutated pro‐
teins are processed into peptides that are presented on HLA classI (HLA I) on the tumor cell surface. CD8+ T cells spe‐
cific for mutated peptides may therefore recognize tumor cells by binding of their T cell receptor (TCR) to the HLA/
peptide complex. b) Stimulation of tumor-specific T cells by dendritic cells (DCs). Tumor proteins are engulfed by DCs
and processed into peptides. The tumor-associated peptides are presented by DCs on HLA class I and HLA class II, to
CD8+ and CD4+ T cells respectively. For proper activation, previously unstimulated (“naive”) T cells also requirestimu‐
lation from co-stimulatory molecules (e.g. CD80) and IL-2. Dendritic cells constitutively express HLA class II (and I)
and co-stimulatory molecules, and the expression in up-regulated upon DC mutation. T cells start producing IL-2
when stimulated through TCR and co-stimulatory molecules. c) Activation of CD4+ and CD8+ T cells induce differen‐
tiation into effector T cells. CD8+ T cells differentiate into cytotoxic effector cells that specifically kill target cells ex‐
pressing the relevant antigen. CD4+ T cells differentiate into T-helper cells secreting high levels of cytokines. Based on
their cytokine profiles, the CD4+ effector cells are conventionally divided into Th1- and Th2-cells.
CD4+ effector T cells are conventionally divided into T-helper 1 (Th1) or T-helper 2 (Th2) cells,
based on their cytokine secretion profiles (Figure 1c).
Interferon-γ (IFNγ), tumour-necrosis factor-α (TNFα) and IL-2 are usually designated as
Immunotherapy of Cancer — Some Up-To-Date Approaches
http://dx.doi.org/10.5772/61227
7
Th1-cytokines, while the Th2-cytokines include IL-4, IL-5, IL-6, IL-10 and IL-13.
Th1 cells support cellular immunity, e.g. by secreting cytokines that induce up-regulation of
HLA on target cells and stimulate macrophages and CD8+ T cells. Th2 cells promote antibody
responses by interaction with B cells.
In cancer immunotherapy, Th1-type responses are generally believed to be desirable.
Antibody responses can only target surface antigens, whereas the CD8+ T cells are able to
recognize intracellular antigens presented on HLA class I. Th1- and Th2-responses are
mutually inhibitory. Th1-cytokines generally promote Th1-differentiation and inhibit Th2-
differentiation, while Th2-cytokines have the opposite effects [5, 7].
Th2-cytokines may therefore suppress the development of cytotoxic anti-tumour responses.
There are considerable experimental data on the effects of individual Th1- or Th2-cytokines.
However, the validity of the Th1/Th2-delineation in humans may be questioned, which could
be our next publication [8].
4. Dendritic cells – The most potent antigen presenting cells
Dendritic cells (DCs) are derived from CD34+ progenitor cells in the bone marrow, but
otherwise constitute a heterogeneous cell type that is widely distributed in different tissues,
including skin, mucosa, lymph nodes and spleen.
Resident DCs in the epidermis (Langerhans cells) and interstitial DCs found in other tissues
[7] are believed to be derived from CD14+ myeloid precursor cells (Figure 2).
Recent studies in mice, however, have suggested that both subsets can be derived from fms-
related tyrosine kinase 3 (Flt3)-expressing myeloid and lymphoid progenitors, and that
plasmacytoid DCs may differentiate into myeloid DCs following viral infection.
Dendritic cells are considered to be the most potent antigen presenting cells and are instru‐
mental in eliciting immune responses. DCs capture antigen in the tissues and then migrate to
regional lymph nodes where they encounter T cells in the paracortal area.
Most DCs in the skin and other tissues have an immature phenotype. These cells are effective
at engulfing antigen and constantly sample their environment, but have a limited ability to
migrate and to stimulate T cells. If immature DCs reach the lymph nodes and present antigens
to T cells, they are likely to induce anergy rather than activation, due to their low expression
of co-stimulatory molecules. In the non-inflammatory setting, the immature DCs thus promote
immunological tolerance by capturing and presenting endogenous antigens. Mature DCs,
however, are potent inducers of immunity.
Maturation of DCs is commonly induced by inflammatory cytokines or by the capture of
microbial ligands that stimulate Toll-like receptors (TLRs).
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Contrary to immature DCs, the mature cells rapidly migrate to regional lymph nodes, as has
been demonstrated in vivo in melanoma patients by Devries and his research group [7].
Moreover, mature DCs strongly up-regulate their expression of HLA class II and co-stimula‐
tory molecules, and are highly effective at activating naïve CD4+.
DCs also present engulfed antigens on HLA class I and may thus directly stimulate CD8+ T
cells.
Finally, the phenotype of mature DCs, including their cytokine secretion pattern, is believed
to direct the differentiation of CD4+ T cells into Th1- or Th2-type cells.
5. Tumour-associated antigens
The tumour-associated antigens comprise tumour-specific antigens, overexpressed antigens,
cancer-germline antigens, viral antigens and tissue-differentiation antigens. Antigens which
are virtually tumour-specific may arise from genomic mutations, e.g. K-RAS or post-transla‐
tional modifications, e.g. MUC-1. Other antigens used in cancer vaccines, like hTERT, survivin,
and HER2/neu, are widely expressed in normal tissues, but overexpressed in tumour cells.
In contrast, the expression of cancer-germline antigens, e.g. the melanoma antigens MAGE-1
and MAGE-3, is restricted to tumour cells and normal germline cells (testis and placenta).
Figure 2. Subsets of dendritic cells (DCs). All DC-subsets are derived from CD34+ haematopoietic profnitor cells in the
bone marrow. Interstitial DCs and Langerhans cells are believed to be of myeloid origin. The plasmacytoid DCs are
traditionally considered to be of lymphoid origin.
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Viral antigens represent attractive vaccine targets for virus-induced cancers and are included
in the prophylactic vaccines mentioned above for cervical carcinoma (Human papilloma virus)
and hepatocellular carcinoma (Hepatitis B virus).
The differentiation antigens are tissue-specific, i.e. expressed only in normal and neoplastic
cells from a particular lineage. These antigens may be utilized in cancer vaccines if an auto‐
immune reaction to the relevant tissue is tolerable.
For instance, prostatitis or vitiligo may represent acceptable adverse effects for patients with
prostate cancer or malignant melanoma, respectively.
Several differentiation antigens are extensively used in cancer vaccines, including prostate-
specific antigen (PSA) and the melanoma antigens Melan a/Mart-1, gp100 and tyrosinase
[6, 7, 8].
6. Background for the present up-to-date tumour-RNA/DC vaccines
6.1. The use of dendritic cells in cancer immunotherapy
Most cancer vaccines have been based on peptides/proteins or tumour lysates that are injected
intradermally. These approaches depend on uptake of vaccine antigen by immature DCs in
the skin, and subsequent DC maturation and migration to lymph nodes. Alternatively, DCs
may be loaded with tumour antigens ex vivo, and then injected into the patient. This strategy
appears attractive, as it may result in enhanced antigen presentation and more effective T-cell
stimulation. Moreover, DC-based vaccines may offer the opportunity of directing the immune
response, by manipulating the DC phenotype.
The first DC-vaccine trials in cancer patients were reported by Hsu et al. in 1996 and Nestle et
al. in 1998 [7]. Promising T-cell responses were obtained, and in recent years, various ap‐
proaches to DC-vaccines have been explored.
Early studies applied immature DCs, but it is now generally believed that a mature phenotype
is desirable.
Targeted loading of DCs in vivo represents another strategy.
Ralph Steinman’s group has explored this option by use of antibodies targeting the receptor
DEC-205 on the DC surface [7]. Their data from animal model indicate that potent T- and B-
cell responses may be elicited.
Alternatively, vaccine antigens might be injected and subsequently transfected into tissue DCs
by use of in vivo electropermeabilization.
6.2. Large-scale generation of dendritic cells
For clinical vaccine production, large quantities of autologous DCs are required. Most studies
make use of monocyte-derived DCs (Mo-DCs).
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On the other hand, DCs may be cultures from CD34+ cells obtained from bone marrow,
umbilical cord blood or cytokine-mobilized peripheral blood progenitor cells.
DCs may also be purified from peripheral blood, e.g. after in vivo mobilization of DCs with
Flt3-ligand.
At present, it is not clear which method results in the best DCs for cancer vaccination.
The only restriction of use of umbilical cord blood comes from the fact that the per cent of
potentially active cells is rather limited and is not enough for bigger scales and clinical
application.
In a study reported by Syme et al., Mo-DCs were compared to DCs generated from CD34+
cells 5, 6, 7). The results demonstrated higher expression of HLA class II and CD86 in the Mo-
DCs, but no difference in the ability to elicit mixed lymphocyte reaction.
Immature DCs, with a phenotype resembling interstitial DCs, can be generated by stimulating
monocytes from peripheral blood with IL-4 and GM-CSF.
The original methods made use of monocytes enriched by adherence.
However, the handling of large numbers of adherent cells is time consuming.
Figure 3. Production of the present RNA/DC-vaccines against malignant melanoma or prostate cancer. Tumor-mRNA
was extracted from autologous melanoma biopsies (melanoma vaccine) or from three prostate cancer cell lines (PC-3,
LNCaP, DU-145; prostate cancer vaccine). Autologus DCs were generated from monocytes obtained from leukaphere‐
sis products. The monocytes were cultured 5 days with IL-4 and GM CSF fro differentiation into immature DCs. Tu‐
mor mRNA was then transfected into DCs by electroporation. After transfection, the DCs were cultured for 2 days
with cytokines promoting maturation and frozen in vaccine batches.
Immunotherapy of Cancer — Some Up-To-Date Approaches
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The production procedure used in the trials performed in Radium Hospital (Inst. Cancer
Research, Oslo, Norway) by the group of Gunnar Kvalheim, Jon Kyte and Paula Lazarova [2,
6, 7] is outlined in Figure 3.
The research group did not make use of adherence, but isolated monocytes from leukapheresis
products by immunomagnetic depletion of lymphocytes.
The monocytes were transferred to gas permeable Teflon bags that allowed the intrinsically
adherent cells to stay in the suspension.
After five days’ culture with IL-4 and GM-CSF, the cells were transfected with tumour-mRNA
(Figure 3).
Finally, the transfected DCs were matured for 2 days ex vivo with TNFα, IL-6, IL-1β and PGE2.
Contrary to most previous studies, a serum-free culture medium was used. Thereby, unwanted
antigens from bovine or human serum were excluded from the vaccine product.
The procedure for DC generation was first established at Radium Hospital by experiments on
healthy donors, as reported by Mu et al. [3, 4] and Lazarova et al. [2, 6, 8], later on patients as
well.
Subsequently, the generation of clinical grade DCs from patients was evaluated as part of the
full-scale preclinical evaluation of the research group in Radium, namely Paula Lazarova et
al. [2, 6, 8].
7. Choice of vaccine antigens
Defined tumour-associated antigens have been targeted in a number of interesting vaccine
trials world-wide, resulting in antigen-specific immune responses. However, there is a limited
evidence of clinical effect, and initial responses are probably vulnerable to tumour escape
through loss of antigen expression. The spectrum of target antigens may be widened by use
of peptide cocktails or allogeneic tumour cell lines. In the vaccine for prostate cancer, as
proposed by the Radium group [2, 3, 4, 5, 6, 7, 8], the employed DCs are transfected with
complete mRNA from allogeneic prostate cancer cell lines. To extend the number of antigens,
three cell lines were combined.
The clinical trial was conducted on patients with hormone refractory cancer, and thus two
hormone-insensitive tumour cell lines were selected (DU-145 and PC-3). A cell line expressing
PSA (LN-CaP) was also included.
PSA is widely used for monitoring disease development and also represents an immunogenic
tumour antigen.
It was considered that the allogeneic antigens included in the tumour cell lines may increase
the risk of side effects, but may also be beneficial.
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T-cell recognizing allogeneic antigens will be primed in the same lymph nodes as the tumour-
specific T cells.
The allo-reaction may therefore result in an inflammatory milieu promoting the development
of effective anti-tumour responses.
It is argued that the majority of tumour antigens are probably specific to each patient and not
even expressed in allogeneic cancer cell lines. The individual tumour antigens are believed to
arise from numerous incidental mutations occurring during the development of tumour.
The melanoma RNA/DC-vaccine, worked out by the Radium group [2, 3, 4, 5, 6, 7, 8], represents
individualized immune-gene therapy. The autologous tumour material as source of mRNA is
used in the procedure (Figure 3) and thereby targets the entire spectrum of tumour antigens
in each individual. Moreover, non-expressed tumour antigens are excluded.
In general, it is believed that personalized vaccines, targeting the unique spectrum of tumour
antigens in each patient, may emerge as a major principle in cancer immunotherapy
The tumour-mRNA strategy is in principle applicable to any cancer form and may prove
particularly useful in rarer cancer forms, where common tumour antigens have not yet been
defined. Contrary to peptide vaccines, the use of cell line/tumour-mRNA bypasses require‐
ments for defined HLA alleles and for expression of identified antigens by tumours.
The mRNA can encode multiple epitopes and recruit a wide spectrum of T cell clones,
including both CD4+helper and CD8+cytotoxic cells.
There is a number of cancer vaccine trials that have applied RNA-transfected DCs.
Certain parts of these studies include use of undefined antigens.
There are definite disadvantages related to the use of undefined antigens.
First, a wide array of possibly harmful autoantigens will be included, suggesting an increased
risk of autoimmune side effects.
Second, the antigens recognized after vaccination will usually not be known.
If HLA-matching peptides can be obtained, T-cell responses to defined antigens may be
demonstrated.
However, most antigens, including unique patient-specific targets, will remain unknown.
The T-cell responses can thus only be characterized to a limited extent.
Third, in a vaccine based on autologous tumour material, each individual will receive different
vaccines.
This complicates the comparison of results from different patients. It should, however, be
recalled, that in any trial on humans the inter-individual variability is immense, even though
the vaccine itself may be fully standardized.
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8. Loading of DCs with antigen
There are several strategies for loading DCs with antigen ex vivo. A number of important trials
have applied simple co-incubation of DCs with peptides, proteins or tumour lysates. Other
interesting vaccine studies have made use of tumour-DC hybrids, i.e. tumour cells that are
fused with DCs. Similar to DCs loaded with tumour lysates or tumour-RNA, these hybrids
may combine the antigen repertoire of tumour cells with the stimulatory capacity of DCs.
However, sufficient numbers of living tumour cells are required. In most patients, clinical scale
vaccine production may therefore only be feasible from allogeneic cell lines, not from autolo‐
gous tumours.
DNA- or RNA-transfection represents other alternatives for DC-loading. It is accepted by the
Radium group that mRNA has certain important advantages compared to DNA.
First, the use of mRNA bypasses the complex issues of transcriptional regulation.
Second, DNA requires entry into the nucleus, while mRNA has direct access to the translation
machinery upon entry into cytoplasm.
In experiments with liposome-mediated loading of plasmid DNA, Saeboe-Larssen et al. found
that only a minute fraction (10ˉ⁴) was detected in the nucleus.
Third, transfected DNA may persist in the cell and encode harmful proteins, while RNA will
rapidly degrade.
The latter point is of particular relevance for the safety of using tumour-derived DNA/RNA,
likely to encode proteins involved in tumour genesis.
The intrinsic instability of RNA, however, also carries a prominent obstacle to clinical use.
The tumour-mRNA may easily degrade if the tumour samples and RNA-preparations are not
carefully handled right from the initial biopsy excision.
Contrary to tumour lysates or tumour/DC-hybrids, tumour–mRNA may be amplified from
small tumour biopsies.
This may be of particular importance if the clinical trials are extended to patients with early-
stage disease, where only small tumours will be available.
Moreover, mRNA-amplification may enable us to make vaccines from small biopsies of
tumours located at difficult sites, e.g. in the brain or visceral organs.
The efficiency of RNA-transfection with conventional RNA/DC co-culture or liposome-
mediated loading is limited, probably reflecting degradation of RNA both outside of the cell
and in endocytic DC compartments.
The limited efficiency results in low intracellular concentrations of the transfected mRNA.
Though immune responses have still been obtained, it is believed that a higher transfection
efficiency is desirable for recruiting a wider spectrum of T-cell clones.
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While some T-cell clones will respond even to low peptide concentrations on the DC surface,
the low affinity clones will require higher concentrations.
Viral vectors represent an effective alternative for both, DNA- and RNA-transfection, but there
are considerable safety concerns and regulatory obstacles regarding their clinical application.
The Radium group [2, 3, 4, 5, 6, 7, 8] has developed an efficient method for mRNA-transfection
by square-wave electroporation, compatible with clinical use.
The electroporation procedure has been optimized for full-scale vaccine production, as worked
out by the group, and applied both, in the melanoma and the prostate cancer trials in Radium.
The measured transfection efficiency is substantially higher than was expected to be obtained
with other methods like liposome-mediated delivery.
In addition to dendritic cells, the research group works also on Epstein-Barr-Virus-trans‐
formed cell lines, monocytes and several cancer cell lines, and the initial results indicate
efficient transfection.
9. Summary
The development and evaluation of immuno-gene therapy of cancer based on tumour-mRNA
transfected dendritic cells, and focused on malignant melanoma and prostate cancer give
certain optimism for future successful application of anti-cancer vaccines.
Acknowledgements
Warmest thanks to the research group of Radium Hospital in Oslo: J.A. Kyte, G. Kvalheim, J.
Nesland, P. Lazarova, L.J. Mu et al. for their active support to provide materials and results
for preparation of this paper.
Author details
Krassimir Metodiev1*, Paula Lazarova2,3, Jon Kyte2, Gunnar Kvalheim2 and Jahn Nesland2
*Address all correspondence to: kr.metod@yahoo.com
1 Dept. Preclinical and Clinical Sciences, Medical University, Varna, Bulgaria
2 Inst. Cancer Research, Univ. Hospital “Radium”, Oslo, Norway
3 Clinical Laboratory, Univ. Hospital “St. Anna”, Varna, Bulgaria
Immunotherapy of Cancer — Some Up-To-Date Approaches
http://dx.doi.org/10.5772/61227
15
References
[1] Г. Капрелян, Кр. Методиев: Терминологичен речник по имунология, Медицина
и физкултура, София, 1990, стр.120
[2] P. Lazarova, M. Lijun, H. Hammerstad, J. Nesland, G. Gaudernack, G. Kvalheim: Ex‐
perimental attempt to introduce a vaccine therapy by using DC-developed from
CD34+ cells. In: Risk Infections and Possibilities for Biomedical Terrorism. IOS Press,
NATO Science Series I, vol. 361, 2004, 134
[3] L.J. Mu, P. Lazarova, G. Gaudernack, S. Saeboe-Larssen, G. Kvalheim: Development
of a clinical grade procedure for generation of mRNA transfected dendritic cells from
purified frozen CD34+ blood progenitor cells. Intl J Immunopathol Pharmacol, vol. 17,
No. 3, 2004, 255-263
[4] L.J. Mu, J.A. Kyte, G. Kvalheim et al.: Immunotherapy with allotumour mRNA-trans‐
fected dendritic cells in androgen resistant prostate cancer patients. Brit J Cancer, 93,
2005, 749-756
[5] J.A. Kyte, L. Mu, S. Aamdal, G. Kvalheim et al.: Phase I/II trial of melanoma therapy
with dendritic cells transfected with autologous tumour mRNA. J Cancer Gene Ther, I,
2006, 14
[6] P. Lazarova, Q. Wu, G. Kvalheim, Z. Suo, K.W. Haakenstad, K. Metodiev, J.M.Nes‐
land: Growth factor receptors in hematopoietic stem cells: EPH family expression in
CD34+ and CD133+ cell populations from mobilized peripheral blood. Intl J Immuno‐
pathol Pharmacol, vol. 19, No. 1, 2006, 49-56
[7] J.A. Kyte, Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic
cells, J Series of Dissertations, Faculty of Medicine, University of Oslo, Radium Hos‐
pital, SiO, 65, 2007
[8] P. Lazarova, G. Kvalheim, K. Metodiev: Is anticancer vaccine possible: Experimental
application of produced mRNA transfected dendritic cells derived from enriched
CD34+ blood progenitor cells. In: Immunodeficiency, InTech, Europe, Open Science,
2012, 77-88
Immunopathology and Immunomodulation16
